| Management target | Revenue FY29 |
|---|
| Revenue growth | 21% YoY increase to ₹196.7 Cr, driven by PFN segment strength. |
|---|---|
| Margins | EBITDA margins improved to 37.2%, supported by operational leverage. |
| Order book | Secured 5 customer approvals for NSS; 12 projects in development pipeline. |
| Demand visibility | Strong visibility in PFN; specialty ingredients expected to recover in H2. |
| Management confidence | Balanced; optimistic on PFN and Battery segments despite rice program pause. |
Growth
PFN revenue surged 57% YoY; total H1 revenue grew 23% YoY to ₹355 Cr.
Outlook
Targets 200,000 tons battery material capacity; expects PFN utilization to ramp over 3 years.
Risks
Lack of visibility on Government fortified rice program restart; high sea freight costs.
Earnings Call Transcript filed with NSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,130.10
- Market cap
- ₹12,764 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 67.8×Sector 48.7×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 2.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue Rs196.7cr (+21% YoY), record EBITDA Rs73.2cr (+32%, 37.2% margin), PAT Rs51.8cr (+11%). Battery-materials pivot and Nandesari FDA approval are the strategic highlights.
Sudeep Pharma Q2 FY27 Results: Net Profit ₹51.8 Cr, Up 10.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹196.7 Cr (+20.9% YoY) and net profit of ₹51.8 Cr (+10.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.8 Cr · +10.7% YoY
Sudeep Pharma Capacity Expansion
Sudeep Pharma received FDA approval for its new 51,200 MT greenfield plant at Nandesari, Gujarat. Commercial operations are expected to commence in H2 FY27 following customer qualification.
- manufacturing capacity
- 51200 MT
Sudeep Pharma Board Meeting Date
Sudeep Pharma has scheduled its Board meeting for 28 October 2026 to approve Q1 and H1 FY27 financial results. No results or monetary figures are disclosed in this intimation.
Sudeep Pharma Other Announcement
The company submitted the mandatory compliance certificate under Regulation 74(5) for the quarter ended September 30, 2026.
Sudeep Pharma Management Change
Mr. Sendhil Pani has ceased to be a Senior Management Personnel of Sudeep Pharma Ltd effective October 2, 2026. This follows the completion of his contractual arrangements.